3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Sarcoma
2
Head & Neck
2
Breast
2
Thoracic
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Lung Neoplasms
29
Carcinoma, Non-Small-Cell Lung
23
Urinary Bladder Neoplasms
4
Melanoma
4
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Adenocarcinoma of Lung
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Colitis
2
Carcinoma, Neuroendocrine
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Radiation Pneumonitis
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
38
Nivolumab
24
atezolizumab
10
Ipilimumab
7
Carboplatin
6
avelumab
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Cyclophosphamide
5
fludarabine
4
cabozantinib
4
Specimen Handling
4
Pemetrexed
4
regorafenib
3
Interleukin-2
3
Gemcitabine
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
lenvatinib
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Biopsy
2
Albumin-Bound Paclitaxel
2
zanidatamab
1
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Immunoglobulin G
×
Thoracic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled